Longboard Pharmaceuticals Operating Income Over Time
| LBPH Stock | USD 59.98 0.02 0.03% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Longboard Pharmaceuticals Performance and Longboard Pharmaceuticals Correlation. Longboard |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Longboard Pharmaceuticals. If investors know Longboard will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Longboard Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.25) | Return On Assets (0.31) | Return On Equity (0.47) |
The market value of Longboard Pharmaceuticals is measured differently than its book value, which is the value of Longboard that is recorded on the company's balance sheet. Investors also form their own opinion of Longboard Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Longboard Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Longboard Pharmaceuticals' market value can be influenced by many factors that don't directly affect Longboard Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Longboard Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Longboard Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Longboard Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Operating Income Analysis
Compare Longboard Pharmaceuticals and related stocks such as Molecular Partners, MediciNova, and Anebulo Pharmaceuticals Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MOLN | 7.1 M | 7.1 M | 7.1 M | 7.1 M | 1.8 M | (2.2 M) | (19.5 M) | (25.8 M) | (37.4 M) | (36.7 M) | (58.3 M) | (63.4 M) | 116.6 M | (61.1 M) | (58.1 M) |
| MNOV | (2 M) | (16.1 M) | (10.9 M) | (4 M) | (9.2 M) | (8.8 M) | (10.9 M) | (13 M) | (15.6 M) | (14 M) | (14.2 M) | (10.2 M) | (14.6 M) | (9.9 M) | (10.4 M) |
| ANEB | (173.3 K) | (173.3 K) | (173.3 K) | (173.3 K) | (173.3 K) | (173.3 K) | (173.3 K) | (173.3 K) | (173.3 K) | (173.3 K) | (3.6 M) | (6.8 M) | (11.8 M) | (8.3 M) | (8.7 M) |
| CSBR | 50 K | (9.1 M) | (6.3 M) | (6.3 M) | (13.2 M) | (10.3 M) | (6.8 M) | (1.4 M) | 270 K | (1.5 M) | 338 K | 607 K | (4.4 M) | (7.4 M) | (7 M) |
| HOWL | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (22.4 M) | (50.1 M) | (56.1 M) | (40.5 M) | (42.5 M) |
| EWTX | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (17.2 M) | (43.2 M) | (22.1 M) | (114.4 M) | (108.6 M) |
| CELC | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (3.3 M) | (6 M) | (7.9 M) | (7.8 M) | (9.6 M) | (28.4 M) | (39.4 M) | (66.2 M) | (62.9 M) |
| CCCC | (16.4 M) | (16.4 M) | (16.4 M) | (16.4 M) | (16.4 M) | (16.4 M) | (16.4 M) | (16.4 M) | (16.4 M) | (35.5 M) | (60.4 M) | (82.1 M) | (129.5 M) | (139 M) | (132.1 M) |
| ASMB | (7.2 M) | (34 M) | (24.9 M) | (19.6 M) | (24 M) | (29.7 M) | (45.3 M) | (52.2 M) | (92.7 M) | (102.7 M) | (64.8 M) | (132.7 M) | (94.1 M) | (64.6 M) | (67.9 M) |
| NXTC | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (23.2 M) | (37.5 M) | (41.2 M) | (70.8 M) | (75.9 M) | (67.6 M) | (71 M) |
| NUVB | (32.1 M) | (32.1 M) | (32.1 M) | (32.1 M) | (32.1 M) | (32.1 M) | (32.1 M) | (32.1 M) | (32.1 M) | (32.1 M) | (43.6 M) | (93.3 M) | (119.7 M) | (99.8 M) | (104.8 M) |
| TIL | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (33.6 M) | (155.6 M) | (226.5 M) | (159.2 M) | (167.1 M) |
| SNSE | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (12.4 M) | (19.5 M) | (37.5 M) | (50.2 M) | (37.1 M) | (38.9 M) |
| GLUE | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (28 M) | (72.9 M) | (112.4 M) | (143.3 M) | (136.1 M) |
| DSGN | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (8.3 M) | (35.8 M) | (67.6 M) | (78.2 M) | (74.3 M) |
| IKNA | (18.5 M) | (18.5 M) | (18.5 M) | (18.5 M) | (18.5 M) | (18.5 M) | (18.5 M) | (18.5 M) | (18.5 M) | (18.5 M) | (44.5 M) | (34.1 M) | (70.9 M) | (75.4 M) | (79.2 M) |
| STOK | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (12.8 M) | (35.7 M) | (53 M) | (86.1 M) | (104.4 M) | (114.8 M) | (109 M) |
Longboard Pharmaceuticals and related stocks such as Molecular Partners, MediciNova, and Anebulo Pharmaceuticals Operating Income description
Operating Income is the amount of profit realized from Longboard Pharmaceuticals operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Longboard Pharmaceuticals is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Longboard Pharmaceuticals | LBPH |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 59.98
Check out Longboard Pharmaceuticals Performance and Longboard Pharmaceuticals Correlation. For more detail on how to invest in Longboard Stock please use our How to Invest in Longboard Pharmaceuticals guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Longboard Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.